Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive Multiple Sclerosis from the Phase III ORATORIO Study

The requested reference [4663dc21ef5ccc496cd55504a8df5de1c4186c45] no longer exists in our database. It has been replaced by the current reference: [c904c79186c34593144def3f9deb358238e895e9]

Authors
Category Primary study
JournalEuropean Journal of Neurology
Year 2018
This article has no abstract
Epistemonikos ID: 84fd8379dc0a4f2578e6b43e7855b49a4e376ad3
First added on: Feb 09, 2025